CEM Corporation & AmbioPharm Form U.S. Partnership for GMP Peptide Production
CEM Corporation and AmbioPharm, Inc. are excited to announce the formation of a partnership for production of GMP peptides for the global market. The partnership will involve an exclusive1 use of CEM’s large-scale microwave peptide synthesis technology for the production of GMP peptides up to multi-kilogram quantities using proprietary scalable reactors. The key benefits of this new relationship are extremely rapid production times, the ability to efficiently produce more difficult peptide sequences, and the ability to incorporate green chemistry protocols. This partnership will enable rapid and efficient production of peptide new chemical entities (NCE’s) using the latest technologies available. With this agreement, AmbioPharm has commenced peptide synthesis operations in its North Augusta facility to better serve customers with expedited microwave synthesis capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005202/en/
Michael Collins, Founder and CEO of CEM Corporation and Chris Bai, Co-Founder and CEO of AmbioPharm (Photo: Business Wire)
CEM’s technology for peptide production utilizes automated large-scale microwave solid-phase peptide synthesis (SPPS) systems that have been established for improving peptide purity and minimizing excess reagents needed. Additionally, CEM has developed proprietary coupling methodologies optimized for elevated temperature reactions2, a unique way to combine the coupling and deprotection reactions into a single step3, and established the use of greener solvents that are more accessible using elevated temperatures4. These unique technology benefits will be licensed to AmbioPharm for GMP production.
AmbioPharm is a recognized leader in cGMP peptide production. The company employs more than 675 employees and recently completed a major expansion at its headquarters in South Carolina, US, adding nearly 56,000 sq. ft of additional peptide manufacturing capacity. The production facility has the purification capability of up to 30 kg/batch and a lyophilization capacity of up to 1,000L. The CEM Liberty Pro synthesizer offers differing reactor sizes (3, 8 and 15 liter) allowing synthesis of batches from 5 g to 500 g of final peptide.
“Peptide based drugs have enormous potential for the future and we are excited to contribute to improving their production process. AmbioPharm is an ideal partner, and we believe this relationship will provide enhanced capabilities for the production of peptide therapeutics.” - Michael J. Collins, Ph.D., President & CEO of CEM Corporation.
“With the addition of CEM’s microwave technology into our GMP peptide manufacturing options, we can offer even better service in terms of expedited delivery for our partners’ products as well as unique capabilities for making longer and more complex peptides accessible with microwave methods.” - Chris Bai, Ph.D., CEO of AmbioPharm Inc.
Both companies will be exhibiting at the upcoming TIDES USA conference in September 2021.
About CEM
CEM Corporation, a private company based in Matthews, North Carolina, is a leading provider of laboratory instrumentation. The company has subsidiaries in the United Kingdom, Germany, Italy, France, Japan, and Singapore, as well as a global network of distributors. CEM designs and manufactures systems for life sciences, analytical laboratories and processing plants worldwide. The company’s products are used in many industries including pharmaceutical, biotech, chemical and food processing, as well as academic research. Further information is available at: https://www.cem.com.
About AmbioPharm, Inc.
AmbioPharm, a part of the Ambio Pharmaceuticals Group, is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services, AmbioPharm produces custom products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. Headquartered in the United States of America and with locations in Europe, the USA, and Asia, AmbioPharm operates internationally with over 14 years of experience and expertise. Further information is available at: https://www.ambiopharm.com.
____________________________
1 With limited provisional exceptions
2 US 10,858,390; US 9,969,769; EP17188963.7; JP2016138090
3 US20170226152; WO2017070512; WO2018044356A1
4 US 11,014,959; WO2019241586A1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005202/en/
Contact information
CEM Corporation
Jonathan M. Collins
VP Business Development
jon.collins@cem.com
Michael J. Karney
Life Science Product Manager
michael.karney@cem.com
AmbioPharm, Inc.
Michael Pennington, Ph.D.
Chief Scientific Officer
mike.pennington@ambiopharm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REI Super Selects SS&C For Superannuation Administration1.5.2025 06:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 04:25:00 EEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 20251.5.2025 04:00:00 EEST | Press release
GIGABYTE Technology, a global leader in computing innovation, will return to COMPUTEX 2025 from May 20 to 23 under the theme "Omnipresence of Computing: AI Forward." Demonstrating how GIGABYTE’s complete spectrum of solutions spanning the AI lifecycle, from data center training to edge deployment and end-user applications reshapes the infrastructure to meet the next-gen AI demands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428101781/en/ From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 2025 As generative AI continues to evolve, so do the demands for handling massive token volumes, real-time data streaming, and high-throughput compute environments. GIGABYTE’s end-to-end portfolio - ranging from rack-scale infrastructure to servers, cooling systems, embedded platforms, and personal computing—forms the foundation to accelerate AI breakthroughs across industr
Carl Haney, Executive Vice President, Global Innovation and Research & Development to Depart The Estée Lauder Companies1.5.2025 01:00:00 EEST | Press release
Today, The Estée Lauder Companies Inc. (NYSE: EL) announced that Carl Haney, Executive Vice President, Global Innovation and Research & Development (R&D), will depart the company effective June 30, 2025 to pursue new opportunities. With Carl’s transition, the company intends to bring in new external talent to drive the next era of transformative innovation in line with its strategic vision of becoming the best, most consumer-centric, prestige beauty company in the world. “Over the past decade, Carl has forged impactful partnerships at the forefront of scientific innovation and delivered breakthrough products and superior formulations across categories, benefits and occasions, while fueling corporate innovation and advanced technologies,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “As we look to the future and delivering our bold Beauty Reimagined vision, we will transform our approach to innovation across the company—which includes e
Clearwater Analytics Completes Acquisition of Beacon, Deepening Risk and Modeling Capabilities30.4.2025 23:15:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN) (“Clearwater”), the most comprehensive technology platform for investment management, today announced it has completed its acquisition of Beacon Platform Inc. (Beacon), a provider of enterprise risk analytics and developer infrastructure. The acquisition strengthens Clearwater’s capabilities in complex portfolio management across both public and private markets, including structured products, private credit, and derivatives. For years, institutional investors have faced a tradeoff between advanced analytics and operational efficiency—navigating rigid legacy systems, endless manual processes, and disconnected data. These fragmented environments slow down decision-making, elevate risk, and obscure a clear, consolidated view of portfolios. Clearwater is changing that. With the integration of Beacon’s cross-asset risk modeling with front-office capabilities and alternative asset intelligence from the acquisitions of Enfusion, Inc. (Enfusion) and Blackstone
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom